Nedaplatin

Nedaplatin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	none;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name Diammine[(hydroxy-κO)acetato(2-)-κO]platinum;
CAS Number	95734-82-0 ;
PubChem CID	9796440;
ChemSpider	7972206;
UNII	8UQ3W6JXAN;
KEGG	D01416 ;
CompTox Dashboard (EPA)	DTXSID8046878 ;
Chemical and physical data
Formula	C2H8N2O3Pt
Molar mass	303.181 g·mol−1
3D model (JSmol)	Interactive image; coordination form: Interactive image;
	SMILES C(C(=O)[O-])[O-].N.N.[Pt+2]; ; coordination form: O=C1O[Pt-2]([NH3+])([NH3+])OC1;
	InChI InChI=1S/C2H3O3.2H3N.Pt/c3-1-2(4)5;;;/h1H2,(H,4,5);2*1H3;/q-1;;;+2/p-1; Key:GYAVMUDJCHAASE-UHFFFAOYSA-M;
	(verify)

Nedaplatin (INN, marketed under the tradename Aqupla) is a platinum-based antineoplastic drug which is used for cancer chemotherapy.^[1] The complex consists of two ammine ligands and the dianion derived from glycolic acid.

Platinum-based drugs are widely employed as antineoplastic agents, especially cisplatin and carboplatin. Due to issues of their toxicity and number of cisplatin-resistant cancer cells, other platinum derivatives have been developed. Nedaplatin is one example of such new drugs.^[2]

References

↑ Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219-33. doi:10.1530/ERC-15-0237. PMID 26113607.
↑ Johnstone TC, Park GY, Lippard SJ (January 2014). "Understanding and improving platinum anticancer drugs--phenanthriplatin". Anticancer Research. 34 (1): 471–6. PMC 3937549. PMID 24403503.

External links

"Aqupla アクプラ" (PDF). Shionogi & Co. March 2007. Archived from the original (PDF) on 2004-08-05.
"Official Shionogi & Co. Website" (in Japanese).

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid26113607-1] Apps MG, Choi EH, Wheate NJ (August 2015). "The state-of-play and future of platinum drugs". Endocrine-Related Cancer. 22 (4): R219-33. doi:10.1530/ERC-15-0237. PMID 26113607.

[2] Johnstone TC, Park GY, Lippard SJ (January 2014). "Understanding and improving platinum anticancer drugs--phenanthriplatin". Anticancer Research. 34 (1): 471–6. PMC 3937549. PMID 24403503.

[1]

[2]